05.06.15
Osiris Therapeutics Inc., a cellular regenerative medicine company, has promoted Alla Danilkovitch, Ph.D., to serve as chief scientific officer.
Danilkovitch has been with Osiris since 2003.
According to a news release from the company, her expertise and leadership has “guided the company in the development of groundbreaking scientific ideas in regenerative medicine.”
Company officials said she has a “proven record” of bringing products from development to market, including the world’s first approved stem cell drug, remestemcel-L, for graft versus host disease as well as BIO4 for bone repair, Cartiform for cartilage repair and Grafix for acute and chronic wounds. Recently, Danilkovitch and her team have developed a pipeline of early-stage products based on cellular constructs in wound care and sports medicine.
“I am pleased the board has confirmed Dr. Danilkovitch as chief scientific officer,” said Lode Debrabandere, Ph.D., president and CEO. “During the past 12 years, Alla has contributed significantly to the advancement of stem cell biology and to the discovery of therapeutic applications of the mesenchymal stem cell with Osiris. We wish Alla and her team success in further advancing the new regenerative medicine pipeline of Osiris.”
Danilkovitch has more than 25 years of broad biomedical research experience including stem cell biology, immunology and cancer research. Prior to joining Osiris in April 2003, Danilkovitch conducted research at the National Cancer Institute of the National Institutes of Health, the Max-Plank Institute of Biochemistry in Munich, Germany, and at Moscow State University. Danilkovitch earned a Ph.D. degree in cell biology and an M.S. degree in cellular immunology and microbiology from Moscow State University.
Osiris Therapeutics is based in Columbia, Md. The 23-year-old company develops regenerative medicine products in the areas of orthopedics, sports medicine and wound care. Its lead investor is Friedli Corporate Finance.
Danilkovitch has been with Osiris since 2003.
According to a news release from the company, her expertise and leadership has “guided the company in the development of groundbreaking scientific ideas in regenerative medicine.”
Company officials said she has a “proven record” of bringing products from development to market, including the world’s first approved stem cell drug, remestemcel-L, for graft versus host disease as well as BIO4 for bone repair, Cartiform for cartilage repair and Grafix for acute and chronic wounds. Recently, Danilkovitch and her team have developed a pipeline of early-stage products based on cellular constructs in wound care and sports medicine.
“I am pleased the board has confirmed Dr. Danilkovitch as chief scientific officer,” said Lode Debrabandere, Ph.D., president and CEO. “During the past 12 years, Alla has contributed significantly to the advancement of stem cell biology and to the discovery of therapeutic applications of the mesenchymal stem cell with Osiris. We wish Alla and her team success in further advancing the new regenerative medicine pipeline of Osiris.”
Danilkovitch has more than 25 years of broad biomedical research experience including stem cell biology, immunology and cancer research. Prior to joining Osiris in April 2003, Danilkovitch conducted research at the National Cancer Institute of the National Institutes of Health, the Max-Plank Institute of Biochemistry in Munich, Germany, and at Moscow State University. Danilkovitch earned a Ph.D. degree in cell biology and an M.S. degree in cellular immunology and microbiology from Moscow State University.
Osiris Therapeutics is based in Columbia, Md. The 23-year-old company develops regenerative medicine products in the areas of orthopedics, sports medicine and wound care. Its lead investor is Friedli Corporate Finance.